ResearcherNational Research CouncilActive in the last 2 years
Greta Bagnolini
Matched on ORCID iD 0000-0001-6237-1235; OpenAlex author ID A5037769166. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 9
2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper
Papers 6
- Targeting RAD51-BRCA2 Interaction to Enhance Synthetic Lethality with Olaparib in Pancreatic Cancer: Development of a Novel Phenyl Furan-Quinoline-Carboxylic A… First author DOI 10.1021/acsmedchemlett.5c00711↗
- Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential activity. Co-author DOI 10.1038/s41420-025-02382-3↗
- An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic lethality in combination with PARP inhibiti… Co-author DOI 10.1016/j.ejmech.2023.116114↗
- Serendipity meets synergism: differential enantiomer activities of a RAD51-BRCA2 disruptor towards a more robust synthetic lethality in pancreatic cancer Co-author DOI 10.21203/rs.3.rs-4031427/v1↗
- Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Ol… Co-author DOI 10.1021/acs.jmedchem.9b01526↗
- Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells. Co-author DOI 10.1016/j.ejmech.2019.01.008↗
Closest collaborators
The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Marinella Roberti · 6 shared papers, 2019–2026 · strength 0.94
- Paper Targeting RAD51-BRCA2 Interaction to Enhance Synthetic Lethality with Olaparib in Pancreatic Cancer: Development of a N… DOI 10.1021/acsmedchemlett.5c00711↗
- Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3↗
- Paper An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic let… DOI 10.1016/j.ejmech.2023.116114↗
- Stefania Girotto · 6 shared papers, 2019–2026 · strength 0.94
- Paper Targeting RAD51-BRCA2 Interaction to Enhance Synthetic Lethality with Olaparib in Pancreatic Cancer: Development of a N… DOI 10.1021/acsmedchemlett.5c00711↗
- Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3↗
- Paper An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic let… DOI 10.1016/j.ejmech.2023.116114↗
- Andrea Cavalli · 6 shared papers, 2019–2026 · strength 0.94
- Paper Targeting RAD51-BRCA2 Interaction to Enhance Synthetic Lethality with Olaparib in Pancreatic Cancer: Development of a N… DOI 10.1021/acsmedchemlett.5c00711↗
- Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3↗
- Paper An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic let… DOI 10.1016/j.ejmech.2023.116114↗
- Mirco Masi · 3 shared papers, 2024–2026 · strength 0.60
- Paper Targeting RAD51-BRCA2 Interaction to Enhance Synthetic Lethality with Olaparib in Pancreatic Cancer: Development of a N… DOI 10.1021/acsmedchemlett.5c00711↗
- Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3↗
- Paper Serendipity meets synergism: differential enantiomer activities of a RAD51-BRCA2 disruptor towards a more robust synthe… DOI 10.21203/rs.3.rs-4031427/v1↗
- Naomi Walsh · 3 shared papers, 2024–2025 · strength 0.52
- Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3↗
- Paper An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic let… DOI 10.1016/j.ejmech.2023.116114↗
- Paper Serendipity meets synergism: differential enantiomer activities of a RAD51-BRCA2 disruptor towards a more robust synthe… DOI 10.21203/rs.3.rs-4031427/v1↗
- Samuel Harry Myers · 3 shared papers, 2024–2025 · strength 0.52
- Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3↗
- Paper An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic let… DOI 10.1016/j.ejmech.2023.116114↗
- Paper Serendipity meets synergism: differential enantiomer activities of a RAD51-BRCA2 disruptor towards a more robust synthe… DOI 10.21203/rs.3.rs-4031427/v1↗
- Giovanni Ferrandi · 2 shared papers, 2025–2026 · strength 0.44
- Paper Targeting RAD51-BRCA2 Interaction to Enhance Synthetic Lethality with Olaparib in Pancreatic Cancer: Development of a N… DOI 10.1021/acsmedchemlett.5c00711↗
- Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3↗
- Shannon R. Nelson · 2 shared papers, 2024–2025 · strength 0.35
- Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3↗
- Paper Serendipity meets synergism: differential enantiomer activities of a RAD51-BRCA2 disruptor towards a more robust synthe… DOI 10.21203/rs.3.rs-4031427/v1↗
- Fabrizio Schipani · 3 shared papers, 2019–2024 · strength 0.34
- Paper An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic let… DOI 10.1016/j.ejmech.2023.116114↗
- Paper Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homolog… DOI 10.1021/acs.jmedchem.9b01526↗
- Paper Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells. DOI 10.1016/j.ejmech.2019.01.008↗
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.